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of imatinib. The anti–CD-20 antibody rituximab led the way for 
immunologic therapeutic approaches for lymphoid malignancies. The 
paradigm of targeting malignancies with increasing greater therapeu-
tic windows is being expanded by both novel agents but also novel 
delivery systems. Furthermore, the next generation of targeting agents 
affords opportunity to minimize host toxicity and increase the likeli-
hood of therapeutic response by targeting specific molecular subsets 
of a single disease. This targeted approach is personalized medicine 
at its best. This presentation will review the history of successes in 
targeted therapy and look to the future for the next generation of 
personalized approaches for hematologic malignancies.
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Summary: Health economic evaluations are central to decisions on 
the availability of new treatments and other health care interventions 
in several jurisdictions across Europe. Health technologies are not 
approved for use in the United Kingdom if they are considered to rep-
resent poor value for money; that is, if their cost-effectiveness exceeds 
around £30,000 (€ 40,000) per quality-adjusted life-year. Personalized 
medicine, in which treatments are prescribed according to patients’ 
characteristics, holds promise for more favorable health outcomes. 
However, as pharmaceutical market shares are potentially reduced as 
a consequence, there is uncertainty as to whether the compensatory 
price adjustments result in cost-effective treatment strategies. It is 
necessary, therefore, to conduct stratified cost-effectiveness analyses 
of treatments based on prognostic factors that reveal populations in 
which treatments are most likely to be effective or less likely to be 
harmful. The cost-effectiveness of pre-prescription genotyping is illus-
trated using a series of case studies: (1) HLA-B*5701 testing, which 
has dramatically reduced the incidence of hypersensitivity reactions 
to abacavir in patients with HIV; (2) VKORC1 and CYP2C9 geno-
typing to guide dose selection with warfarin; (3) HLA-A*3101 testing 
for the reduction in the incidence of carbamazepine-induced cutane-
ous adverse drug reactions; (4) testing for genetic polymorphisms in 
UGT1A1 and irinotecan-induced neutropenia and diarrhea; and (5) 
CYP2C19 testing before clopidogrel treatment in patients with acute 
coronary syndrome. With the exception of abacavir, a specific limita-
tion of these analyses, which introduces considerable uncertainty to 
the estimation of cost-effectiveness, relates to the evidential standards 
for demonstration of the clinical effectiveness of tests.
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Summary: Drug safety is an essential element for the successful oper-
ation and efficiency of any health care system. In the last decade, 
Nigeria—like most emerging countries—has put in place structures 
and mechanisms to ensure the safety of medicines used by its large 
population of ~170 million. Before this period, the focus was mainly 
on the comprehensive registration of medicines as well as ensur-
ing that good quality medicines are allowed into circulation. The 
proportion of substandard/counterfeit medicines in the market has 
decreased significantly.
In 2004, Nigeria was admitted into the WHO International Drug 
Monitoring Scheme as its 74th member after initial pharmacovigilance 
(PV) activities in a number of locations in the country. Its PV system is 
based on voluntary spontaneous reporting of adverse drug reactions. 
The operating system is the Vigiflow linked to the Uppsala Monitoring 
Centre and currently holds > 10,000 ICSRs in its local database. The 
country has recently set up a zonal (regional) PV structure with 6 cent-
ers, in consonance with its geopolitical set-up, which are linked to the 
National Pharmacovigilance Centre in the capital city Abuja. A PV pol-
icy document has just been launched to guide PV activities in the country.
The main thrust of the PV activities is the sensitization of the gen-
eral population and health care providers to raise the level of aware-
ness, as well as further advocacy of supervising regulatory bodies to 
ensure improved role of professionals and other stakeholders in PV. 
The current challenges include the engagement of the pharmaceutical 
industries, local and international, and the practitioners in herbal 
medicine. Again, coverage of the pediatric and geriatric population 
has also come into view.
In all, PV has made tremendous progress in Nigeria in the decade 
since its membership in the WHO international monitoring network.
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Most medicines in Europe are not authorized for use in children: 
almost 50% of medicines prescribed to children in the hospital are 
unlicensed for their age group or prescribed off-label. There are major 
practical and ethical issues in relation to studying medicines in chil-
dren, especially in neonates. To improve the situation, a pediatric 
regulation entered into force in 2007, and the European Medicines 
Agency identified drugs as priority medicinal products for evalua-
tion in children. The TINN project was selected by the FP7 program 
to evaluate ciprofloxacin and fluconazole. It was launched in 2008, 
and data evaluating ciprofloxacin are presented. Ciprofloxacin is a 
fluoroquinolone for the treatment of multiresistant gram-negative 
bacterial sepsis with an acceptable safety profile and a useful pattern 
of bacterial susceptibility. The TINN project included: (1) a litera-
ture review on ciprofloxacin in pediatric patients2; (2) juvenile animal 
studies using Phenopus3; and (3) a survey in Europe included 193 
NICUs from 32 countries. (4) Results showed that ciprofloxacin is 
used in 25% of NICUs, but indications and dosages vary widely4; a 
ciprofloxacin method was developed in low sample volumes5; (5) a 
population pharmacokinetic study (Liverpool, United Kingdom and 
Paris, France) included 51 neonates, showing that ciprofloxacin clear-
ance was dependent on current weight, gestational and postnatal age, 
and renal function and that volume of distribution was dependent of 
current weight6. A PIP for ciprofloxacin was not validated and no 
Paediatric-Use Marketing Authorisation (PUMA) will be obtained 
because the studies required were not possible to perform and the 
market is too small to expect viability of a new formulation. However, 
the studies conducted within TINN allow dosage recommendations to 
treat suspected or proven resistant gram-negative infections.
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